Reata Pharmaceuticals (RETA) PT Raised to $51 at Citi on Potential Omav Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharma (RETA) Climbs 12% After Announcing FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreich’s Ataxia
October 13, 2022 4:40 PM EDTReata Pharma (NASDAQ: RETA) Climbs 12% After Announcing FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreichs Ataxia
... MoreReata Pharma (RETA) Announces FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreich’s Ataxia
October 13, 2022 4:38 PM EDTReata Pharmaceuticals,... More
